Supplemental materials for the manuscript entitled "APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis: a proteomics analysis from two prospective cohorts"
Description
Mendeley supplemental figure 1. Participants disposition. Forty-eight patients in cohort 1 were treated with steroids alone and thirty-five patients received steroids plus adalimumab in cohort 2. Mendeley supplemental figure 2. Representative photos illustrate disease progression in cohort2. Mendeley supplemental figure 3. Plasma proteomics profiling of SJS/TEN before and after the combination treatment. (A) Comparative Venn diagram of plasma proteins between AP group and RP group. (B) The volcano plot demonstrated the differential encapsulation of plasma proteins between AP and RP. (C) GO analysis of the candidates for differentially expressed proteins in plasma from AP and RP. (D) The candidates for differentially expressed proteins in plasma from RP were analyzed using KEGG software, and the top 20 KEGG pathways were demonstrated in the bubble map. Mendeley supplemental figure 4. (A) The heat map of hierarchical clustering indicated the candidates for differentially expressed proteins in the AP and RP plasma. (B) ELISA analysis of APOA4 levels in the plasma of HC (n=21) and SJS/TEN patients in AP/RP (n=21). Mendeley supplemental figure 5. (A and B) Protein levels of APOA4 were increased in RP compared with AP by western blot analysis. Mendeley supplemental figure 6. Clinical correlation analysis between TNF-α decline and APOA4 increase. Mendeley supplemental figure 7. Comparison of plasm cytokine levels before and after the treatment. Mendeley supplemental figure 8. NF-κB signaling pathway. Mendeley supplemental figure 9. TNF signaling pathway. Mendeley supplemental figure 10. The diagnostic criteria of SJS/TEN by the RegiSCAR study group. Mendeley supplemental table 1. Demographic and clinical characteristics of the patients in two cohorts. Mendeley supplemental table 2. Culprit drugs in two cohorts. Mendeley supplemental table 3. The candidates of differentially expressed proteins in plasma before and after the combination treatment. Mendeley supplemental table 4. Correlation analysis of APOA4 levels with associated factors of SJS/TEN severity. Mendeley supplemental table 5. Linear regression analysis of factors associated with ScorTEN in SJS/TEN patients. Mendeley supplemental table 6. Characteristics in included RCT and case series. Mendeley supplemental table 7. The clinical scoring system, “SCORTEN”, for predicting mortality in SJS/TEN.